These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Correlation between serum p53 antibody and chemosensitivity in patient with esophageal cancer].
    Author: Wang MH, Li YP, Wang XD, Zhang H, Xiong LH, Huang HZ.
    Journal: Ai Zheng; 2004 Apr; 23(4):467-70. PubMed ID: 15087041.
    Abstract:
    BACKGROUND & OBJECTIVE: Studies have revealed that overexpression of p53 protein has close relation to induction of drug resistance in cancer patients and it can be used as a predictor for chemosensitivity of tumor. Recently, it has been found that specific p53 antibody (p53-Ab) presented in the serum of cancer patients with p53 protein overexpression. Furthermore, the presence of serum p53-Ab is closely correlated with p53 protein overexpression. Thus, serum p53-Ab could theoretically be useful in predicting chemosensitivity in cancer patients. In the present study, we investigated whether preoperative serum p53-Ab is correlated with the postoperative chemosensitivity of esophageal cancer, which was analyzed using in vitro drug response assay. METHOD: Serum analysis of p53 antibodies was performed by enzyme-linked immunosorbent assay (ELISA) in 38 patients with esophageal cancer preoperatively, then surgically resected specimens were analyzed for their chemosensitivity to cisdichlorodiammineplatinum (DDP),5-fluorouracil (5-FU), and Adriamycin (ADM) by in vitro drug response assay MTT colorimetry. RESULTS: Serum p53-Ab was present in 47.3% of the patients with esophageal cancer. The positive rate of serum p53-Abs in patients was significantly different from that in healthy blood donors (P< 0.01). The positive rate of serum p53-Ab was 25%(5/20) for the patients at stage I and II, and 72.2%(13/18) for the patients at stage III and IV.A significant correlation between serum p53-Ab positive rate and TNM stage was observed (P< 0.05). The positive rate of serum p53-Ab were 21.5%(3/14), 50%(6/12), 75% (9/12) for the patients with well, moderately,and poorly differentiated tumors, respectively. There was significant correlation between serum p53-Ab positive rate and tumor differentiation (P< 0.05). The chemosensitivity to DDP, 5-FU, and ADM (11.1%,16.1%,and 16.1%, respectively) of the patients with positive serum p53-Ab was significantly lower than that of the patients with negative p53-Ab (60%, 45%, and 35%; P< 0.01,P< 0.05, and P< 0.05, respectively). CONCLUSION: p53-Ab is not only a prognostic marker for patients with esophageal cancer, but also a predictor of their response to chemotherapy.
    [Abstract] [Full Text] [Related] [New Search]